Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

BACKGROUND: The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that adalimumab was efficacious and well-tolerated for the treatment of hand and/or foot psoriasis through 28 weeks. OBJECTIVE: To evaluate the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulin, Y, Crowley, JJ, Langley, RG, Unnebrink, K, Goldblum, OM, Valdecantos, WC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229025/
https://www.ncbi.nlm.nih.gov/pubmed/23790018
http://dx.doi.org/10.1111/jdv.12198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229025/
https://www.ncbi.nlm.nih.gov/pubmed/23790018
http://dx.doi.org/10.1111/jdv.12198

Ejemplares similares